Novel biomarkers for acute heart failure syndromes are broadly classified by mechanisms including inflammation, renal stress, extracellular matrix remodeling, oxidative stress, and neurohormonal regulation.
Do novel biomarkers improve risk stratification and short-term prognosis in patients with acute heart failure syndromes?
This review highlights recent advances in novel biomarkers for early risk stratification and prognosis in acute heart failure syndromes.
BACKGROUND: Early risk stratification of patients with acute heart failure syndrome (AHFS) can guide the decision to admit the patient to hospital and the choice of therapy. METHODS: Standard review methodology using Medline and Google scholar from the years 2006-present. Papers before 2006 were reviewed when necessary. RESULTS: Biomarkers used in AHFS are broadly classified based on their mechanism of action: inflammation, renal stress, extracellular matrix remodeling, oxidative stress, cardiac myocyte stress, and neurohormonal regulation. CONCLUSION: This paper provides a review for clinicians and medical scientists highlighting the most recent advances in biomarkers with application in AHFS.
Avellino et al. (Mon,) conducted a review in Acute heart failure syndrome (AHFS). Novel biomarkers was evaluated. Novel biomarkers for acute heart failure syndromes are broadly classified by mechanisms including inflammation, renal stress, extracellular matrix remodeling, oxidative stress, and neurohormonal regulation.